Search

Author/Creator Riggs, Matthew M.

1. Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. (December 2014)

Authors:
Riggs, Matthew M.; Seman, Leo J.; Staab, Alexander; MacGregor, Thomas R.; Gillespie, William; Gastonguay, Marc R.; Woerle, Hans J.; Macha, Sreeraj
Journal:
British journal of clinical pharmacology
Issue:
Volume 78:Number 6(2014:Dec.)
Page Start:
1407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. Issue 3 (21st January 2020)

Authors:
Perkins, Bruce A.; Soleymanlou, Nima; Rosenstock, Julio; Skyler, Jay S.; Laffel, Lori M.; Liesenfeld, Karl‐Heinz; Neubacher, Dietmar; Riggs, Matthew M.; Johnston, Curtis K.; Eudy‐Byrne, Rena J.; Elmokadem, Ahmed; George, Jyothis T.; Marquard, Jan; Nock, Valerie
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 22:Issue 3(2020)
Page Start:
427
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗